TEVA/MYL—“Regulatory blockage” as in objections from antitrust regulators. There are only five large global generic-drug companies remaining, so combining two of them is likely to be viewed as anticompetitive by at least one regulatory body who has veto power over the deal.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.